Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene repertoire in 14 patients who received Rituximab post allo-HCT and explore clinicobiological correlations. All experienced antigenic triggers, CMV, EBV re-activation and chronic GvHD and had been treated with Rituximab. Skewing of TRBV genes was observed: 3 TRBV genes accounted for half of the repertoire. Oligoclonal pattern with expanded clonotypes was common. Patients with oligoclonality exhibited frequently cGvHD. Longitudinal samples in one revealed distinct clonotypes, suggesting clonal drift. T-LGL leukemia of donor origin with mixed chimerism eventually developed. In conclusion, we report development of oligoclonal T-LGLs after Rituximab post allo-HCT, alluding to antigen selection. Persistence of this phenomenon likely reflects strong antigenic stimulation by viruses and/or cGVHD aggravated by Rituximab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2018.1543881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Tachyplesin Antimicrobial Peptide from Theraphosidae Spiders with Potent Antifungal Activity Against .
Microorganisms
December 2024
Key Laboratory of Genetic Evolution & Animal Models, Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, and Sino-African Joint Research Center, New Cornerstone Science Laboratory, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming 650201, China.
The venoms of Theraphosidae spiders have evolved into diverse natural pharmacopeias through selective pressures. is a global health threat that frequently causes life-threatening meningitis and fungemia, particularly in immunocompromised patients. In this study, we identify a novel anti- peptide, QS18 (QCFKVCFRKRCFTKCSRS), from the venom gland of China's native spider species by utilizing bioinformatic tools.
View Article and Find Full Text PDFRetrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer.
Cancers (Basel)
December 2024
Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka 812-0018, Japan.
: Neoantigens have attracted attention as ideal therapeutic targets for anti-tumour immunotherapy because the T cells that respond to neoantigens are not affected by central immune tolerance. Recent findings have revealed that the activation of CD4-positive T cells plays a central role in antitumor immunity, and thus targeting human leukocyte antigen (HLA) class II-restricted neoantigens, which are targets of CD4-positive T cells, is of significance. However, there are very few detailed reports of neoantigen vaccine therapies that use an HLA class II-restricted long peptide.
View Article and Find Full Text PDFTreatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.
Blood Cancer J
January 2025
Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Introducing robot-assisted kidney transplantation in a high-volume centre in Denmark: a pilot and feasibility study.
J Robot Surg
January 2025
Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Ole Maaloes Vej 24, 2. Floor, 2200, Copenhagen, Denmark.
Article Synopsis
- Robot-assisted kidney transplantation (RAKT) shows potential to reduce surgical complications compared to open kidney transplantation (OKT), although no randomized trials have been conducted yet.
- This study aimed to introduce RAKT at Copenhagen University Hospital and evaluate early surgical outcomes using data from June 2022 to May 2023, involving both living and deceased donor cases.
- Results indicated favorable outcomes with 16 RAKTs performed, no major intra-operative events, a median operative time of 223 minutes, and a low 90-day complication rate, supporting the foundation for a future randomized trial comparing RAKT to OKT.
Insights into proliferative glomerulonephritis with monoclonal immunoglobulin deposits - is it really monoclonal or not?
Curr Opin Nephrol Hypertens
January 2025
Control of the immune response B and lymphoproliferation, CNRS UMR 7276, INSERM UMR 1262, University of Limoges, Centre de référence de l'amylose AL et autres maladies par dépôts d'immunoglobuline monoclonale, Limoges, France; Service de néphrologie et Centre National de référence amylose AL et autres maladies à dépôts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France.
Article Synopsis
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is characterized by specific glomerulonephritis and has unique challenges in detecting monoclonal Ig deposits.
- Recent findings suggest that many cases of PGNMID-IgG3 may not actually be monoclonal, necessitating better detection methods.
- Advanced techniques like mass spectrometry and sequencing can improve identification of monoclonal Ig, helping to differentiate it from oligoclonal deposits in PGNMID cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!